linjc16/ctgov huggingface dataset:
An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the relationship between attempted and/or completed suicide and reported experience of chronic pain among an adult veteran population. Specific aims include a) examining the experience of chronic pain between patients who have either attempted and/or completed suicide, non-suicide attempt mental health patients, and non-mental health chronic pain patients and b) determining possible differences in reported experiences of chronic pain based on mental and physical diagnoses, age, gender, ethnicity, occupation, and patient's recorded perceptions of depression and/or quality of life. As articulated in the Amendment approved on June 13, 2008, additional areas of interest include histories of neurological disease (e.g. traumatic brain injury) and/or mental health diagnoses. History of both neurologic disease and mental health diagnoses will also be identified by chart review (per approval obtained June 13, 2008). As such this study will also compare differences (e.g., mental health, neurological disease) between veterans who have history of a suicide attempt, completion, or a lifetime history of suicidality and matched control veterans without a history of suicide attempts, completions, or lifetime history of suicide. The relationship between suicidal behavior, attempted/completed suicide, and reported Post Traumatic Stress Disorder (PTSD) symptoms among an adult veteran population is also of interest. Additionally, this data set will be used to complete a validation study regarding the Self-Directed Violence Classification System (SDVCS). Specifically, relevant information in subject chart notes regarding self-directed violence (SDV) will be used to categorize thoughts and behaviors according to the SDVCS.

Official Title
-----------------
An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans

Conditions
-----------------
Posttraumatic Stress Disorder, Traumatic Brain Injury, Suicide Attempt

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over the age of 18 Record of a suicide attempt or completion between October 2004 and February 2006 Exclusion Criteria: For cases: upon chart review, no record of a suicide attempt or completion within the specified time frame

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Suicidal Ideation |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
posttraumatic stress disorder, traumatic brain injury, Suicide Attempt, Veterans
Physiotherapy Efficiency on Child Asthma

Study Overview
=================
Brief Summary
-----------------
The study aim is to compare usual asthma crisis treatment of hospitalized children with usual treatment associated to sophrology.

Official Title
-----------------
Physiotherapy Efficiency With Caycedian Sophrology on Child Asthma: Randomized, Controlled Study

Conditions
-----------------
Child, Asthma Crisis

Intervention / Treatment
-----------------
* Other: usual treatment
* Other: usual treatment + sophrology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: child (6 to 17 years old) hospitalized in pediatric unit for asthma crisis Exclusion Criteria: patient who can't participate because of his healthcare (resuscitation...) impossibility to measure Peak Expiratory Flow (PEF)

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: usual treatment<br>usual treatment | Other: usual treatment<br>* usual treatment<br>|
| Experimental: usual treatment + sophrology<br>usual treatment + sophrology | Other: usual treatment + sophrology<br>* usual treatment + sophrology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak Expiratory Flow (PEF) |  | 1 day |
Effect of Smokeless Tobacco on Anterior Segment

Study Overview
=================
Brief Summary
-----------------
Observational, comparative, cross-sectional study

Detailed Description
-----------------
To evaluate the acute and chronic effects of smokeless tobacco (ST) on the anterior segment parameters using optical biometry. Observational, comparative, cross-sectional study Place and Duration of Study: Department of Ophthalmology, Kahramanmaras Sutcu Imam University. The study included 53 right eyes of 53 subjects (study group), who used ST and 54 right eyes of 54 healthy subjects without ST (control group). Following a full ophthalmological examination, baseline measurements were taken with optical biometry and these measurements were repeated at 5, 30 and 60 mins after using ST.

Official Title
-----------------
Evaluation of the Effect of Smokeless Tobacco on Anterior Segment Parameters

Conditions
-----------------
Eye Manifestations, Tobacco; Use, Harmful, Tobacco Chewing Toxicity

Intervention / Treatment
-----------------
* Device: optical biometry measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A subject who use ST A subject who was not using ST Exclusion Criteria: Refractive disorder Systemic chronic disease (diabetes, hypertension, neurological, etc.) Ocular trauma Ocular surgery Glaucoma Optic disc abnormalities Congenital anomaly

Ages Eligible for Study
-----------------
Minimum Age: 26 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Smokeless tobacco<br>Individuals using smokeless tobacco | Device: optical biometry measurement<br>* The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.<br>|
| No smokeless tobacco<br>Individuals who do not use smokeless tobacco | Device: optical biometry measurement<br>* The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central Corneal Thickness (CCT) | Change in Central Corneal Thickness (CCT | Baseline to 60 minutes after intervention | 
| Axial Length (AL) | Change in Axial Length (AL) | Baseline to 60 minutes after intervention | 
| Anterior chamber deep (ACD) | Change in Anterior chamber deep (ACD) | Baseline to 60 minutes after intervention | 
| Lens thickness (LT) | Change in Lens thickness (LT) | Baseline to 60 minutes after intervention | 
| Pupillary diameter (PD) | Change in Pupillary diameter (PD) | Baseline to 60 minutes after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smokeless tobacco, Optical biometry, pupillar diameter
Ultrasound Detection of Radiographically Negative Fractures of Elbow in Children

Study Overview
=================
Brief Summary
-----------------
Fractures of an elbow are common in children. Accurate initial diagnosis is crucial for the management of the fractures of an elbow. In young children the fractures may be suspected clinically but missed on x-rays due to mostly non-ossified cartilage that is not visible on a regular x-ray. We propose that every x-ray negative, but clinically suspicious elbow trauma in children can be additionally evaluated using high resolution US.

Conditions
-----------------
Fractures, Bone

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signing Informed consent Exclusion Criteria: Unwillingness to sign informed consent. Any fracture of the same hand or forearm before or after an avaluated event.

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction.

Study Overview
=================
Brief Summary
-----------------
In patients with acute ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) may cause thrombus dislodgment and impaired microcirculatory reperfusion. This study was designed to test the hypothesis that thrombus aspiration before standard PCI may improve acute myocardial reperfusion, measured by ST-segment resolution (STR) and myocardial blush grade (MBG), compared with standard PCI.

Detailed Description
-----------------
Consecutive STEMI patients, admitted within 12 hours of symptom onset and scheduled for primary PCI are randomly assigned to two treatment strategies: standard PCI including stenting and abciximab (group1) or thrombus aspiration with Pronto™ extraction catheter (Vasc.solutions, Minneapolis) before standard PCI (group2). Patients with cardiogenic shock, previous infarction or thrombolytic therapy are excluded.

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Device: Coronary thrombus aspiration catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ST-segment elevation myocardial infarction patients undergoing primary angioplasty within 12 hours from symptom onset. Exclusion Criteria: Cardiogenic shock, previous infarction, previous coronary bypass surgery,bundle branch block or pacemaker induced rythm, controindications to IIb/IIIa inhibitors.

Ages Eligible for Study
-----------------
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Coronary thrombus aspiration catheter|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ST-segment resolution immediately after primary angioplasty |  |  | 
| Myocardial Blush grade after angioplasty. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coronary TIMI flow grade, |  |  | 
| distal embolization, |  |  | 
| no reflow |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute myocardial infarction, primary angioplasty, myocardial reperfusion, thrombus aspiration
Wiser Choices in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Patients who are hospitalized because of a heart attack are prescribed a number of medicines to help the heart heal. The investigators will examine different ways in which clinicians share information about those treatment options with patients and the impact that this can have on patients' choices and health.

Official Title
-----------------
Wiser Choices in Acute Myocardial Infarction

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Other: AMI Choice Decision Aid
* Other: Usual Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 18 and 90 Hospitalized at Saint Marys Hospital A primary diagnosis of AMI, Have heart rate, blood pressure, troponin and creatinine measurements, There is an intention to offer treatment medications Are able and willing to provide informed consent Exclusion Criteria: Have not had a myocardial infarction Have significant cognitive, visual impairment, Non-English speaker Have a Do Not Intubate/Do Not Resuscitate (DNI/DNR) status Will be discharged to a nursing home AMI is not the presumptive diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Decision Aid<br>Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid. | Other: AMI Choice Decision Aid<br>* The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.<br>|
| Active Comparator: Usual Care<br>Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner. | Other: Usual Care<br>* Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increases adherence to cardiac medications with proven benefits |  | 6 months | 
| Reduces patients' decisional conflict (increase patient decisional quality) |  | During hospital stay | 
| Decreases rehospitalization rates and death |  | 5 weeks and 6 months | 
| Increase patient knowledge of medication to help the heart heal |  | During hospital stay | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Decision aid, Heart attack, myocardial infarction
Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle

Study Overview
=================
Brief Summary
-----------------
This study will assess 75-100 patients for feeding issues following surgery for single ventricle.

Detailed Description
-----------------
We wish to consent 75-100 subjects at Children's Healthcare of Atlanta. If subjects take part in this study, the following will happen: Prior to discharge, the parent/guardian will be given a home feeding log and Parents will bring the feeding log to regularly scheduled clinic visits. Clinic staff will also weigh the child and measure head circumference at each clinic visit. The investigators will look at the child's medical record to obtain other information including diagnosis, surgery, oxygen saturation levels and medications. The parent/guardian will be asked to fill out a questionnaire about their stress and uncertainty caring for their baby after heart surgery. They will be asked to fill out the same questionnaire 3 times: First time will be before they leave the hospital after the baby's surgery, while still a patient on the Cardiac Step Down Unit (CSU). Second time will be at the Sibley Heart Center Cardiology clinic after they have been home for approximately 4 weeks. Third time will be at the Sibley Heart Center Cardiology clinic after they have been home for approximately 12 weeks or at the time of the routine cardiac cath prior to their second stage surgery. It should take about 15 minutes to fill out the questionnaire. The questionnaire is the only research procedure. The data from the feeding log and clinic visits will be submitted to Cincinnati Children's, the primary site for this study.

Official Title
-----------------
Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle

Conditions
-----------------
Congenital Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single ventricle patients who have received the Norwood Stage I operation. Exclusion Criteria: Infants with chromosomal anomalies or other non-cardiac conditions (cleft palate, necrotizing enterocolitis [NEC] or other gastrointestinal [GI] anomalies) Prematurity less than 37 weeks Infants greater than 30 days of age at Stage I palliation Parents who cannot read or understand questionnaires administered as a part of the study.

Ages Eligible for Study
-----------------
Maximum Age: 30 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight gain |  | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congenital heart disease, Single ventricle, Infant feeding
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Study Overview
=================
Brief Summary
-----------------
To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.

Conditions
-----------------
Acute Pseudophakic Cystoid Macular Edema

Intervention / Treatment
-----------------
* Drug: Bromfenac
* Drug: Ketorolac
* Drug: Diclofenac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract surgery Males and females 18 years and older Able to provide written informed consent Exclusion Criteria: Complicated cataract surgery, particularly posterior capsule rupture and vitreous loss Pre-Existing macular pathology, including macular edema, macular scar, macular hole, or macular pucker History of Uveitis Ipsilateral intraocular surgery prior to cataract surgery CME greater than one year duration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: Bromfenac<br>* 1 drop (in the eye) Instill one drop in the affected eye twice daily for three months<br>|
| Active Comparator: 2<br> | Drug: Ketorolac<br>* 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months<br>|
| Active Comparator: 3<br> | Drug: Diclofenac<br>* 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute Pseudophakic Cystoid Macular Edema |  | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity |  | 5 months |
ATAC - Pharmacokinetics (PK) Sub-Protocol

Study Overview
=================
Brief Summary
-----------------
To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..

Official Title
-----------------
A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Anastrozole
* Drug: Tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for entry into the main ATAC trial 1033IL/0029 Patients must have been taking ATAC trial medication for at least 3 months (i.e. patients must have reached at least visit 2 of the main ATAC study) Patients should be taking their medication in the mornings for at least 3 months Patients must be 100% compliant over the preceding fourteen days Exclusion Criteria: Excluded from entry into the main ATAC trial (1033IL/0029) Patients whose concurrent treatment includes diazepam or drugs which might affect tamoxifen steady state levels or steroid hormone status. These include ketoconazole (antifungal) or related compounds

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Arimidex 1mg + Nolvadex placebo | Drug: Anastrozole<br>* 1mg, orally, once daily<br>* Other names: Arimidex;|
| Active Comparator: 2<br>Arimidex placebo + Nolvadex 20mg | Drug: Anastrozole<br>* 1mg, orally, once daily<br>* Other names: Arimidex;Drug: Tamoxifen<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;|
| Active Comparator: 3<br>Arimidex 1mg + Nolvadex 20mg | Drug: Tamoxifen<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Steady state plasma trough concentrations of tamoxifen, desmethyltamoxifen and anastrozole |  | 24±4 hours after previous dose |